Mid-day Healthcare Movers: Amarin & Amicus Therapeutics Jump On Positive News
(Thomson Reuters ONE) -
Amarin Corporation (NASDAQ:AMRN) is the notable percentage gainer and added
10.71% to $14.54 and made a new 52-week high of $15.40 earlier in the session as
U.S. patent examiners appear poised to approve a family of key patents that
could protect its AMR101 prescription fish oil pill from generic competition
through 2030. Moreover, this morning analyst at Jefferies lifted its price
target on the stock by $2 to $26, citing bullish on the prospects for approval.
The firm has a "Buy" rating on the stock.
AVI BioPharma, Inc. (NASDAQ:AVII) turned lower and was recently down 1.50% to
$0.64, off session high of $0.70 despite the FDA has issued Orphan Drug Status
to the company for its Ebola/Marburg viruses prevention drug. Over the past
three months, the stock has shown heavy selling and lost over 59%. Technically,
the stock has been showing strong support at around $0.60 area. Yesterday, the
stock was up 6.56% to $0.65.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) said that the company has positive
results from an ongoing Phase 2 open-label drug-drug interaction study to
evaluate the safety and pharmacokinetic effects of the pharmacological chaperone
AT2220 co-administered with enzyme replacement therapy for Pompe disease.
Shares of the company are up 2.43%, extending its yesterday's rally of 6.67%.
Bristol Myers Squibb Co. (NYSE:BMY) announced that its board of directors
another $3 billion in share buyback. This is in addition to the company's prior
approval of $3 billion repurchase program of which the company has pending
commitment for approximately $340 million remaining. In total out of the
company's total authorized $6 billion, the company has approximately $3.34
billion remains to be used for future repurchases, the company said. Shares of
BMY are up 1.65%.
CEL-SCI Corporation (NYSEAMEX:CVM) is showing unusual volume and gained 3.82% to
$0.359 on average volume as the company's CEO Geert Kersten signaled that the
firm's Phase 3 trials for Multikine treatment for head and neck cancer are going
well. He noted in a national radio interview that "Based on everything that
we've seen in the clinic so far, if we continue to see the same results, we will
have the first non-toxic cancer therapy."
MRI Interventions Inc (OTCBB:MRIC) resumed its uptrend and rose 10.24% to $1.40
after falling over 5% in the prior session. Late Monday, the company along with
Brainlab AG today announced an alliance with Tocagen Inc. in the fight against
the most aggressive form of brain cancer, recurrent high grade gliomas including
glioblastoma multiforme (GBM).
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1622491]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.06.2012 - 13:01 Uhr
Sprache: Deutsch
News-ID 1128488
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 141 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Mid-day Healthcare Movers: Amarin & Amicus Therapeutics Jump On Positive News
"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
